Neuropharmacology in the Neurocritical Care Unit

doi:10.1017/9781107587908.007

Chapter 7 - Neuropharmacology in the Neurocritical Care Unit

Published online by Cambridge University Press: 24 July 2019

Sarah M. Adriance

Edited by

Michel T. Torbey

Show author details

Michel T. Torbey: Affiliation:
Ohio State University

Book contents

Get access

Summary

From protein binding alterations to frequent drug–drug interactions, from hypermetabolic states to anuria, there exists a multitude of reasons that the therapeutic interventions of choice must be individualized in a critically ill patient. The principles of clinical pharmacology provide the basis of optimizing a safe and effective drug regimen. The four major subdivisions of pharmacology include pharmacokinetics, pharmacodynamics, pharmacotherapeutics, and toxicology. Simply stated, pharmacokinetics and pharmacodynamics focus on what the body does to the drug and what the drug does to the body, respectively. The following pharmacokinetic and pharmacodynamics factors must be taken into consideration to optimize effectiveness and to minimize toxicity.

Type: Chapter
Information: Neurocritical Care , pp. 62 - 77

DOI: https://doi.org/10.1017/9781107587908.007 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Kress, JP, Pohlman, AS, O’Connor, MF, Hall, JB (2000). Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 342: 1471–1477.Google Scholar

Seder, DB, Riker, RR, Jagoda, A, Smith, WS, Weingart, SD (2012). Emergency neurological life support: airway, ventilation, and sedation. Neurocrit Care 17: S4-S20.Google Scholar

Mirski, MA, Muffelman, B, Ulatowski, JA, Hanley, DF (1995). Sedation for the critically ill neurologic patient. Crit Care Med 23: 2038–2053.Google Scholar

Teitelbaum, JS, Ayoub, O, Skrobik, Y (2011). A critical appraisal of sedation, analgesia and delirium in neurocritical care. Can J Neurol Sci 38: 815–825.CrossRef Google Scholar PubMed

Brophy, GM, Bell, R, Claassen, J, et al. (2012). Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 17: 3–23.CrossRef Google Scholar PubMed

Treiman, DM, Meyers, PD, Walton, NY, et al. (1988). A comparison of four treatments for generalized convulsive status epilepticus. Verterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 339: 792–798.Google Scholar

Rowe, AS, Goodwin, H, Brophy, GM, et al. (2014). Seizure prophylaxis in neurocritical care: A review of evidence-based support. Pharmacotherapy 34: 396–409.Google Scholar

Temkin, NR, Dikmen, SS, Wilensky, AJ, et al. (1990). A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med 8: 497–502.Google Scholar

Bratton, SL, Chestnut, RM, Ghajar, J et al. (2007). Guidelines for the management of severe traumatic brain injury. XIII. Antiseizure prophylaxis. J Neurotrauma 24: S83–86.Google Scholar

Chang, BS, Lowenstein, DH (2003). Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1: 10–16.CrossRef Google Scholar

Dikmen, SS, Temkin, NR, Miller, B, Machamer, J, Winn, HR (1991). Neurobehavioral effects of phenytoin prophylaxis of posttraumatic seizures. JAMA 10: 1271–1277.Google Scholar

Temkin, NR, Dikmen, SS, Anderson, GD, et al. (1999). Valproate therapy for prevention of posttraumatic seizures: a randomized trial. J Neurosurg 4: 593–600.CrossRef Google Scholar

Szaflarski, JP, Sangha, KS, Lindsell, CJ, Shutter, LA (2010). Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care 2: 165–172.Google Scholar

Connolly, ES, Rabinstein, AA, Carhuapoma, JR, et al. (2012). Guidelines for the management of aneurysmal subarachnoid hemorrhage. Stroke 43: 1711–1737.Google Scholar

Diringer, MN, Bleck, TP, Claude Hemphill, J III, et al. (2011). Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society’s Multidisciplinary Consensus Conference. Neurocrit Care 2: 211–240.Google Scholar

Naidech, AM, Kreitner, KT, Janjua, N, et al. (2005). Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke 3: 583–587.Google Scholar

Rosengart, AJ, Juo, JD, Tolentino, J, et al. (2007). Outcome in patients with subarachnoid hemorrhage treated with antiepileptic drugs. J Neurosurg 2: 253–260.CrossRef Google Scholar

The Brain Trauma Foundation, The American Association of Neurological Surgeons, The Joint Section on Neurotrauma and Critical Care (2000). Guidelines for cerebral perfusion pressure. J Neurotrauma 17: 507–511.Google Scholar

Kamel, H, Navi, BB, Nakagawa, K, Hemphill, JC 3rd, Ko, NU (2011). Hypertonic saline versus mannitol for the treatment of elevated intracranial pressure: a meta-analysis of randomized clinical trials. Crit Care Med 39(3): 554–559.CrossRef Google Scholar PubMed

Weant, KA, Martin, JE, Humphries, RL, Cook, AM (2010). Pharmacologic options for reducing the shivering response to therapeutic hypothermia. Pharmacotherapy 30: 830–841.Google Scholar

Doufas, AG, Lin, CM, Suleman, MI, et al. (2003). Dexmedetomidine and meperidine additively reduce the shivering threshold in humans. Stroke 34: 1218–1223.Google Scholar

Mokhtarani, M, Mahgoub, AN, Morioka, N, et al. (2001). Buspirone and meperidine synergistically reduce the shivering threshold. Anesth Analg 93: 1233–1239.Google Scholar

Arpino, PA, Greer, DM (2008). Practical pharmacologic aspects of therapeutic hypothermia after cardiac arrest. Pharmacotherapy 28: 102–111.Google Scholar

Choi, AH, Ko, SB, Presciutti, M, et al. (2011). Prevention of shivering during therapeutic temperature modulation: the Columbia anti-shivering protocol. Neurocrit Care 14: 389–394.CrossRef Google Scholar PubMed

Badjatia, N, Strongilis, E, Prescutti, M, et al. (2008). Metabolic impact of shivering during therapeutic temperature modulation: the Bedside Shivering Assessment Scale. Stroke 39: 3242–3247.Google Scholar

Diringer, MN, Bleck, TP, Claude Hemphill, J 3rd, et al. (2011). Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society’s Multidisciplinary Consensus Conference. Neurocrit Care 15: 211–240.Google Scholar

Connolly, ES Jr, Rabinstein, AA, Carhuapoma, JR, et al. (2012). Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 43: 1711–1737.Google Scholar

Ekelund, A, Reinstrup, P, Ryding, E, et al. (2002). Effects of iso- and hypervolemic hemodilution on regional cerebral blood flow and oxygen delivery for patients with vasospasm after aneurysmal subarachnoid hemorrhage. Acta Neurochir (Wien) 144: 703–712; discussion 712–713.Google Scholar

Lennihan, L, Mayer, SA, Fink, ME, et al. (2000). Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a randomized controlled trial. Stroke 31: 383–391.Google Scholar

Egge, A, Waterloo, K, Sjoholm, H, et al. (2001). Prophylactic hyperdynamic postoperative fluid therapy after aneurysmal subarachnoid hemorrhage: a clinical, prospective, randomized, controlled study. Neurosurgery 49: 593–605; discussion 605–606.Google Scholar

Allen, GS, Ahn, HS, Preziosi, TJ, et al. (1983). Cerebral arterial spasm: a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med 308: 619–624.CrossRef Google Scholar PubMed

Dorhout Mees, SM, Rinkel, GJ, Feigin, VL, et al. (2007). Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev CD000277.Google Scholar

Nimodipine [package insert]. Detroit, MI: Caraco Pharmaceutical Laboratories, Ltd; 2012. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6a161d9-7e7a-4711-ba0e-c9040c42268d (accessed December 2018).Google Scholar

Haley, EC Jr, Kassell, NF, Torner, JC (1993). A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 78: 537–547.Google Scholar

Haley, EC Jr, Kassell, NF, Torner, JC, Truskowski, LL, Germanson, TP (1994). A randomized trial of two doses of nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 80: 788–796.CrossRef Google Scholar PubMed

Dorhout Mees, SM, Algra, A, Vandertop, WP, et al. (2012). Magnesium for aneurysmal subarachnoid hemorrhage (MASH-2): a randomised placebo-controlled trial. Lancet 380: 44–49.Google Scholar

Kramer, AH, Fletcher, JJ (2011). Locally-administered intrathecal thrombolytics following aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. Neurocrit Care 14: 489–499.Google Scholar

Badjatia, N, Topcuoglu, MA, Pryor, JC, et al. (2004). Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm. Am J Neuroradiol 25: 819–826.Google Scholar

Ehtisham, A, Taylor, S, Bayless, L, et al. (2009). Use of intrathecal nicardipine for aneurysmal subarachnoid hemorrhage-induced cerebral vasospasm. South Med J 102: 150–153.Google Scholar

Goodson, K, Lapointe, M, Monroe, T, Chalela, JA (2008). Intraventricular nicardipine for refractory cerebral vasospasm after subarachnoid hemorrhage. Neurocrit Care 8: 247–252.Google Scholar

Webb, A, Kolenda, J, Martin, K, Wright, W, Samuels, O (2010). The effect of intraventricular administration on mean cerebral blood flow velocity measured by transcranial doppler in the treatment of vasospasm following aneurysmal subarachnoid hemorrhage. Neurocrit Care 12: 159–164.CrossRef Google Scholar PubMed

Schmidt, U, Bittner, E, Pivi, S, Marota, JJ (2010). Hemodynamic management and outcome of patients treated for cerebral vasospasm with intrarterial nicardipine and/or milrinone. Anesth Analg 110: 895–902.CrossRef Google Scholar PubMed

Albanese, E, Russo, A, Quiroga, M, et al. (2010). Ultrahigh-dose intraarterial infusion of verapamil through an indwelling microcatheter for medically refractory severe vasospasm: initial experience. J Neurosurg 113: 913–922.Google Scholar

Keuskamp, J, Murali, R, Chao, KH (2008). High-dose verapamil in the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg 108: 458–463.Google Scholar